News Search Results
Apr 27, 2025, 20:00 ET Nona Biosciences' Partner Pfizer Presents Preclinical Data on TOP1i-Based ADC Targeting MSLN at AACR Annual Meeting 2025
Mass., April 27, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced that its partner, Pfizer, has presented preclinical
More news about: Nona Biosciences
Apr 25, 2025, 22:19 ET Formosa Pharmaceuticals and Saval Corporation Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain
Laboratorios Saval. About Formosa Pharmaceuticals, Inc. Formosa Pharmaceuticals, Inc. (6838.TW) is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary nanoparticle formulation technology (APNT®),
More news about: Formosa Pharmaceuticals Inc.,
Apr 25, 2025, 19:22 ET WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS
precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Willow's FutureGrownTM biotechnology platform allows large-scale production with sustainability at its core. Willow's R&D team has a proven track record of developing and commercializing
More news about: Willow Biosciences Inc.
Apr 25, 2025, 13:00 ET Rgenta Therapeutics Presents Preclinical Data on RGT-61159, a Potent, Selective Oral Small Molecule Inhibitor of MYB, Demonstrating Robust Anti-Tumor Activity in Several Monotherapy Models of AML and Synergistic Activity when Combined with Standard of Care for AML
Mass., April 25, 2025 /PRNewswire/ -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders,
More news about: Rgenta Therapeutics
Apr 25, 2025, 13:00 ET Marengo to Share Updated Clinical Results from STARt-001 Phase 1/2 Clinical Trial Featuring Invikafusp Alfa Monotherapy Activity in PD1 Resistant Tumors at Upcoming AACR 2025 Clinical Plenary Oral Presentation
April 25, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy, today announced an upcoming clinical plenary oral presentation at the American
More news about: Marengo Therapeutics
Apr 25, 2025, 13:00 ET Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
Elevation Oncology cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval are inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may
More news about: Elevation Oncology
Apr 25, 2025, 13:00 ET Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting
Mass., April 25, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will present preclinical data of FL-501 in a poster
More news about: Leap Therapeutics, Inc.
Apr 25, 2025, 12:47 ET AMGEN ANNOUNCES $900 MILLION MANUFACTURING EXPANSION, CREATION OF 350 NEW JOBS IN OHIO
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Apr 25, 2025, 08:00 ET Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering
April 25, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ: INTS), ("Intensity" or the "Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase
More news about: Intensity Therapeutics Inc.
Apr 25, 2025, 07:43 ET AbbVie Reports First-Quarter 2025 Financial Results
and overall survival (OS) compared to investigator's choice (IC) chemotherapy. AbbVie and Xilio Therapeutics, a clinical-stage biotechnology company, announced a collaboration and option-to-license agreement that will combine AbbVie's oncology expertise with Xilio's proprietary tumor-activation
More news about: AbbVie
Apr 25, 2025, 05:45 ET Contact Levi & Korsinsky by May 20, 2025 Deadline to Join Class Action Against Sana Biotechnology, Inc.(SANA)
April 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
Apr 24, 2025, 17:31 ET IBRANCE's Market Growth Marks a Significant Step Forward in Metastatic HR+/HER2− Breast Cancer Treatment Landscape | DelveInsight
landscape, including clinical and non-clinical stage products, and the key metastatic breast cancer companies, including Roche, RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd.,
More news about: DelveInsight Business Research, LLP
Apr 24, 2025, 15:32 ET Hammes celebrates two project milestones at Moffitt Cancer Center SPEROS FL
open in January 2026, Moffitt's new Speros campus is a global innovation hub targeting cancer care, research and biotechnology. Hammes is serving as program manager for the campus' new 120,000-square-foot outpatient and proton facility, as well as the new 240,000-square-foot
More news about: Hammes
Apr 24, 2025, 12:00 ET VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Non-Infectious Anterior Uveitis
April 24, 2025 /PRNewswire/ -- VivaVision Biotech (VivaVision), a clinical-stage, privately held biotechnology company focused on developing innovative treatments for ocular diseases, today announced positive topline results
More news about: VivaVision Biotech
Apr 24, 2025, 11:00 ET Primo's Taoyuan Facility Achieves PIC/S GMP Certification, Paving the Way for Global Expansion in Nuclear Medicine.
TAIPEI, April 24, 2025 /PRNewswire/ -- Primo Biotechnology Co., Ltd. ("Primo") proudly announces that its Taoyuan pharmaceutical facility has successfully passed inspection by Taiwan Food and Drug Administration
More news about: Primo Biotechnology Co., Ltd.
Apr 24, 2025, 10:32 ET SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:
More news about: The Schall Law Firm
Apr 24, 2025, 10:01 ET At-Home Genetic Testing Market to Reach $4.5 Bn By 2027 in the short run and $20.2 Bn By 2035 Globally, at 20.3% CAGR: Allied Market Research
potential health risks and tailor lifestyle and treatment plans accordingly. Further, rising investment in research and development within the biotechnology sector is expected to drive the market growth. Enhanced R&D activities have contributed to continuous innovation and improved testing panels,
More news about: Allied Market Research
Apr 24, 2025, 10:00 ET NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension)
Group B.V., is partnered with well-established global biopharmaceutical companies and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace. About HarrowHarrow,
More news about: Nordic Pharma
Apr 24, 2025, 09:09 ET NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update
April 24, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today issued a shareholder letter from Chief Executive Officer
More news about: NeuroSense
Apr 24, 2025, 09:00 ET Araceli Biosciences Closes $11.2M Seed Financing to Change the Pace of Drug Discovery
Ore., April 24, 2025 /PRNewswire/ -- Araceli Biosciences, a pioneering biotechnology company revolutionizing high-content imaging and AI-powered analysis, today announced the successful completion of its Seed funding round, raising
More news about: Araceli Biosciences
Apr 24, 2025, 09:00 ET Araceli Biosciences Closes $11.2M Seed Financing to Change the Pace of Drug Discovery
Ore., April 24, 2025 /PRNewswire/ -- Araceli Biosciences, a pioneering biotechnology company revolutionizing high-content imaging and AI-powered analysis, today announced the successful completion of its Seed funding round, raising
More news about: Araceli Biosciences
Apr 24, 2025, 08:30 ET Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation
April 24, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), a biotechnology company that pioneered the use of human hyaluronidase for subcutaneous drug delivery, today filed a patent infringement lawsuit against Merck Sharp
More news about: Halozyme Therapeutics, Inc.
Apr 24, 2025, 08:00 ET Beacon Therapeutics Announces ARVO 2025 Presentation on Preliminary 6-Month Data from its Phase 2 DAWN Trial of laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP)
24, 2025 /PRNewswire/ -- Beacon Therapeutics Holdings Limited ('Beacon Therapeutics' or 'the Company'), a leading clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases, today announces an upcoming presentation on 6-month
More news about: Beacon Therapeutics
Apr 24, 2025, 08:00 ET Stealth BioTherapeutics to Present New Bevemipretide Data at ARVO Annual Meeting
April 24, 2025 /PRNewswire/ -- Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced
More news about: Stealth BioTherapeutics Inc.
Apr 24, 2025, 08:00 ET Alcyone Therapeutics Announces Strategic Financing to Advance an Expanded Pipeline of Pediatric-Focused Precision Therapeutics for Severe Neurological Diseases
NationwideChildrens.org/Research. About Alcyone TherapeuticsAlcyone Therapeutics is a clinical-stage biotechnology company committed to transforming pediatric care through a diversified portfolio of precision CNS therapeutics and dosing platforms. The Company
More news about: Alcyone Therapeutics